Plain-English translation of NCT05661461 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called in people with advanced cancers (tumors that have spread or grown into nearby tissues) who have moderate liver problems. Researchers want to understand whether is safe to give to these patients and how the body processes the medication, since liver function affects how drugs work in the body.
Most cancer medications haven't been carefully studied in patients with liver impairment, even though liver health is important for how the body processes drugs. This trial will help doctors understand whether and how to safely use this medication in patients whose livers don't work normally.
If you enroll, you will receive intravenous infusions of the medication over 30 minutes on two separate days (Days 1 and 8) at a study center. Researchers will monitor your health closely, checking blood work and watching for any side effects to understand whether the medication is safe and how your body processes it. The study involves multiple visits over time, and you'll need to meet certain health requirements throughout your participation.
AI-generated summary from trial data ยท Jun 13, 2026 ยท Not medical advice
United States
Phase
Safety & dosing
Sponsor
Aadi Bioscience, Inc.
Enrollment target
~15 participants
Started
November 2022
Primary completion
August 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.